J Crawford. Show Affiliations »
Abstract
Mesh: See more » Antineoplastic Agents/administration & dosageAntineoplastic Agents/pharmacokineticsAntineoplastic Agents/therapeutic useDrug CarriersDrug Delivery Systems/methodsFilgrastimGranulocyte Colony-Stimulating Factor/analogs & derivativesGranulocyte Colony-Stimulating Factor/pharmacokineticsGranulocyte Colony-Stimulating Factor/therapeutic useHumansInterferon alpha-2Interferon-alpha/pharmacokineticsInterferon-alpha/therapeutic useLiposomesNeoplasms/geneticsPolyethylene Glycols/administration & dosagePolyethylene Glycols/chemistryPolyethylene Glycols/pharmacokineticsPolyethylene Glycols/therapeutic useProteins/administration & dosageProteins/pharmacokineticsProteins/therapeutic useRecombinant Proteins
Substances: See more » Antineoplastic AgentsDrug CarriersInterferon alpha-2Interferon-alphaLiposomesProteinsRecombinant ProteinsGranulocyte Colony-Stimulating FactorpegfilgrastimPolyethylene GlycolsFilgrastimpeginterferon alfa-2a
Year: 2002 PMID: 12173406 DOI: 10.1016/s0305-7372(02)80001-9
Source DB: PubMed Journal: Cancer Treat Rev ISSN: 0305-7372 Impact factor: 12.111